You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
绿叶制药(02186.HK)精神分裂症创新药获中国批准上市
阿思达克 01-14 12:09
绿叶制药(02186.HK)公布,注射用利培酮微球(II)「瑞欣妥」已获中国药监局批准上市,是集团第一个由长效缓释平台开发的获批上市创新制剂。

瑞欣妥是用於治疗精神分裂症的每两周注射一次的缓释微球肌肉注射制剂。

除中国市场外,瑞欣妥还在多个海外市场进行开发。目前其在美国处於上市申报阶段, 在欧洲完成I期临床试验,同时未来计划在多个新兴市场开发并上市。其专利在中国(包括大陆和香港)、美国、欧洲、日本、韩国、俄罗斯、加拿大、澳大利亚均获得授权,专利期 至2032年。(ic/u) ~

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account